α-1-Antichymotrypsin promotes β-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease

Lars N.G. Nilsson, Kelly R. Bales, Giovanni DiCarlo, Marcia N. Gordon, Dave Morgan, Steven M. Paul, Huntington Potter

Research output: Contribution to journalArticlepeer-review

124 Scopus citations

Abstract

α1-Antichymotrypsin (ACT), an acute-phase inflammatory protein, is an integral component of the amyloid deposits in Alzheimer's disease (AD) and has been shown to catalyze amyloid β-peptide polymerization in vitro. We have investigated the impact of ACT on amyloid deposition in vivo by generating transgenic GFAP-ACT-expressing mice and crossing them with the PDGF-hAPP/V717F mice, which deposit amyloid in an age-dependent manner. The number of amyloid deposits measured by Congo Red birefringence was increased in the double ACT/amyloid precursor protein (APP) transgenic mice compared with transgenic mice that only expressed APP, particularly in the hippocampus where ACT expression was highest, and the increase was preceded by elevated total amyloid β-peptide levels at an early age. Our data demonstrate that ACT promotes amyloid deposition and provide a specific mechanism by which inflammation and the subsequent upregulation of astrocytic ACT expression in AD brain contributes to AD pathogenesis.

Original languageEnglish
Pages (from-to)1444-1451
Number of pages8
JournalJournal of Neuroscience
Volume21
Issue number5
DOIs
StatePublished - Mar 1 2001

Keywords

  • Alzheimer's disease
  • Amyloid deposition
  • Amyloid β-peptide
  • Congo Red
  • Inflammation
  • Transgenic mice
  • α1-antichymotrypsin

Fingerprint

Dive into the research topics of 'α-1-Antichymotrypsin promotes β-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease'. Together they form a unique fingerprint.

Cite this